Navigation Links
Monash researchers uncover cancer survival secrets
Date:8/11/2008

A team of Monash University researchers has uncovered the role of a family of enzymes in the mutation of benign or less aggressive tumours into more aggressive, potentially fatal, cancers in the human body.

The discovery, published today in the international journal Cancer Cell, provides valuable insights into how cancer cells develop and mutate, and could ultimately change treatment options for sufferers around the world.

Team leader, Associate Professor Tony Tiganis, from the Department of Biochemistry and Molecular Biology at Monash University said their work showed that the enzymes known as protein tyrosine kinases (PTKs) had a greater role than previously thought in the rate of growth and tumour change over time.

"We already know that PTKs are associated with several types of aggressive cancers, including colon, breast and lung cancers," Associate Prof Tiganis said.

"What we have discovered is that PTKs have an important role to play as cancer cells grow and mutate to become potentially more aggressive tumours.

"The more we can learn about how tumours develop, the more we are able to prevent their growth in the future. There are already drugs that inhibit particular PTKs in the late stages of treatment. Our discovery could change the timing of when and how those or similar drugs are administered."

Assoc Professor Tiganis said all cells routinely divide and duplicate during growth. An entire genome is replicated and divides equally into two daughter cells. Sometimes things go wrong. To try to prevent this, nature has installed key cell surveillance checkpoints where molecular 'wardens' slow down DNA replication to try and correct mistakes to get the cell duplication back on track.

Normally, PTKs are turned off in the face of compromised DNA replication, but when PTK pathways remain on, unscheduled cell division can take place where cells distribute their DNA unevenly between the two resulting daughter cells. As a result, tumour cells can accumulate or lose genes and chromosomes, and gain a growth and survival advantage.

"Our studies have shown that PTK pathways are intimately associated with the regulation of checkpoint responses during DNA replication," Assoc Prof Tiganis said.

"We have identified one mechanism by which PTKs may remain activated and allow cancer cells to bypass the molecular warden of DNA replication. They may lack a key enzyme called TCPTP." Experiments published in the prestigious journal Cancer Cell have been conducted using cells grown in the laboratory. "But the big question remains. What happens in the real world of human cancers?"

The Monash team will now apply their laboratory findings to human cancer samples to see if they contain low levels of TCPTP and hopefully cement the role of this protein in cancer formation and development.


'/>"/>

Contact: Samantha Blair
samantha.blair@adm.monash.edu.au
039-903-4841
Monash University
Source:Eurekalert

Related biology news :

1. Monash researcher receives prestigious Commonwealth Health Ministers award
2. USC researchers identify alternate pathway that leads to palate development
3. Researchers block damage to fetal brain following maternal alcohol consumption
4. In scientific first, Einstein researchers correct decline in organ function associated with old age
5. Researchers find cancer-inhibiting compound under the sea
6. UT Health Science Center researchers study diet and autism
7. UGA researchers win $9.2 million stem cell grant from NIH
8. Broad Institute researchers introduce next generation tool for visualizing genomic data
9. Spanish researchers discover significant leatherback turtle nesting beaches in the Caribbean
10. ORNL researchers analyze material with colossal ionic conductivity
11. UNH researchers tag first-ever free-swimming leatherback turtles in New England
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... 2016 , ... During a two day program for start-up ... CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business basics ... Denver area business community, shared his top fundamental learnings in building an effective, ...
(Date:4/28/2016)... April 28, 2016 The report ... Brayton Cryocoolers), Service (Technical Support, Product Repairs & Refurbishment, ... Global Forecast to 2022", published by MarketsandMarkets, the global ... by 2022, at a CAGR of 7.29% between 2016 ... Tables and 94 Figures spread through 159 Pages and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... investments in recruiting top industry experts, and expanding its LATAM network and logistics ... tools for clients to manage their clinical trial projects. , The expansion will ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was ... since 1987. Since then, he has served in a number of key leadership positions ... the program and exposition committees. In his professional career, Dr. Gardner is the director ...
Breaking Biology Technology: